| scholarly article | Q13442814 |
| P2093 | author name string | Jin Hyoung Kim | |
| Kyu-Won Kim | |||
| Jeong Hun Kim | |||
| Young Suk Yu | |||
| Chang Sik Cho | |||
| P2860 | cites work | Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. | Q30665533 |
| How the diabetic eye loses vision. | Q30836019 | ||
| Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. | Q31125777 | ||
| Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation | Q31805054 | ||
| Molecular mechanisms of vascular permeability in diabetic retinopathy | Q33887339 | ||
| SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier | Q34206194 | ||
| Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 | ||
| Early cellular and molecular changes induced by diabetes in the retina | Q34338727 | ||
| Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate | Q34409210 | ||
| Perindopril: possible use in cancer therapy | Q34620597 | ||
| Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin | Q35791973 | ||
| The role of clusterin in retinal development and free radical damage | Q36172074 | ||
| Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system | Q37318301 | ||
| Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats | Q37358195 | ||
| Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. | Q40473859 | ||
| Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. | Q44028824 | ||
| Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy | Q44247079 | ||
| Pathophysiological consequences of VEGF-induced vascular permeability | Q46349878 | ||
| Suppression of ocular inflammation in endotoxin-induced uveitis by blocking the angiotensin II type 1 receptor. | Q46618800 | ||
| Quantitative receptor autoradiographic analysis for angiotensin II receptors in bovine retinal microvessels: quantitation with radioluminography | Q48278726 | ||
| AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha. | Q53572840 | ||
| Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. | Q54092413 | ||
| Increased serum angiotensin converting enzyme activity in type I insulin-dependent diabetes mellitus: its relation to metabolic control and diabetic complications | Q72797749 | ||
| Retinal neovascularization is prevented by blockade of the renin-angiotensin system | Q73295556 | ||
| Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus | Q74058742 | ||
| Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells | Q74405505 | ||
| Diabetic retinopathy | Q75217418 | ||
| The role of clusterin in in vitro ischemia of human retinal endothelial cells | Q81243004 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 621-628 | |
| P577 | publication date | 2008-12-24 | |
| P1433 | published in | Journal of Cerebral Blood Flow & Metabolism | Q14663525 |
| P1476 | title | Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy | |
| P478 | volume | 29 |
| Q97425097 | Activation of mas restores hyperoxia-induced loss of lung epithelial barrier function through inhibition of apoptosis |
| Q36990241 | Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice. |
| Q44948732 | Administration of sesamol improved blood-brain barrier function in streptozotocin-induced diabetic rats. |
| Q37564793 | Advances in the medical treatment of diabetic retinopathy |
| Q46483060 | Aliskiren decreases oxidative stress and angiogenic markers in retinal pigment epithelium cells |
| Q27025635 | Alternative pathways in the development of diabetic retinopathy: the renin-angiotensin and kallikrein-kinin systems |
| Q53124062 | Angiotensin II receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. |
| Q37304677 | Animal models of diabetic retinopathy: summary and comparison |
| Q98613393 | Apigenin and Ethaverine Hydrochloride Enhance Retinal Vascular Barrier In Vitro and In Vivo |
| Q37801912 | Current approaches to the management of diabetic retinopathy and diabetic macular oedema |
| Q45964657 | Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. |
| Q49724247 | Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System. |
| Q43039163 | Diabetic maculopathy and retinopathy. Functional and sociomedical significance |
| Q37892915 | Diabetic microvascular complications: possible targets for improved macrovascular outcomes |
| Q33914589 | Effect of angiotensin II type 1 receptor blocker and angiotensin converting enzyme inhibitor on the intraocular growth factors and their receptors in streptozotocin-induced diabetic rats. |
| Q47093719 | Effects of quercetin on the expression of MCP-1, MMP-9 and VEGF in rats with diabetic retinopathy |
| Q38464030 | Hydration, fluid regulation and the eye: in health and disease |
| Q37644348 | Hypoxia-induced angiotensin II by the lactate-chymase-dependent mechanism mediates radioresistance of hypoxic tumor cells |
| Q38990297 | Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors |
| Q37884176 | Inflammation in diabetic retinopathy |
| Q33703836 | Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy |
| Q37580070 | Intracardiac renin-angiotensin system and myocardial repair/remodeling following infarction |
| Q50524854 | Investigation of barrier characteristics in the hyaloid-retinal vessel of zebrafish. |
| Q58748151 | Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy |
| Q57750182 | Loss of Angiotensin-Converting Enzyme 2 Exacerbates Diabetic Retinopathy by Promoting Bone Marrow Dysfunction |
| Q37678807 | Mediators of ocular angiogenesis |
| Q34766422 | Microvascular responses to cardiovascular risk factors. |
| Q38050159 | Neuropeptides and diabetic retinopathy |
| Q37204025 | Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review |
| Q64058295 | Perturbed Biochemical Pathways and Associated Oxidative Stress Lead to Vascular Dysfunctions in Diabetic Retinopathy |
| Q38940171 | Recent perspectives on the delivery of biologics to back of the eye. |
| Q50116104 | Relationship between G proteins coupled receptors and tight junctions |
| Q42098043 | Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction |
| Q43442634 | Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas |
| Q99561828 | Retinal Physiology and Circulation: Effect of Diabetes |
| Q39238324 | Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) axis in the Pathogenesis of Diabetic Retinopathy |
| Q60301147 | Serum microRNA-221 as a biomarker for diabetic retinopathy in patients associated with type 2 diabetes |
| Q48623673 | Small GTPase ARF6 controls VEGFR2 trafficking and signaling in diabetic retinopathy. |
| Q35005977 | TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis |
| Q34096257 | The development of blood-retinal barrier during the interaction of astrocytes with vascular wall cells |
| Q50947386 | The effect of a systemic angiotensin receptor blocker on vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy. |
| Q35226462 | The kallikrein-kinin system in diabetic retinopathy |
| Q34364177 | Validation of structural and functional lesions of diabetic retinopathy in mice |
| Q34066200 | Vascular dysfunction associated with type 2 diabetes and Alzheimer's disease: a potential etiological linkage |
| Q27028225 | Vitreous mediators in retinal hypoxic diseases |
Search more.